FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198355843> ?p ?o ?g. }

• W3198355843 endingPage "93" @default.
• W3198355843 startingPage "86" @default.
• W3198355843 abstract "The incidence of real-world pneumonitis and durvalumab rechallenge during chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown.We retrospectively evaluated the medical records of 302 consecutive patients diagnosed with non-small cell lung cancer who started chemoradiotherapy between May 2018 and May 2019.Median age was 70 (range: 40-87) years. Volume of lung parenchyma that received 20 Gy (V20) exceeded 35% in 2% and mean lung dose exceeded 20 Gy in 1% of patients. Durvalumab consolidation was delivered to 225 patients (75%). Overall, 83% (n = 251), 34% (n = 103), 7% (n = 21), and 1% (n = 4) of the patients developed any grade of pneumonitis, symptomatic pneumonitis, ≥grade 3 pneumonitis, and fatal (grade 5) pneumonitis, respectively. Corticosteroids were administered to 25% of the patients to treat pneumonitis. Multivariate analysis identified the predictive factors for the development of symptomatic pneumonitis: V20 Gy or more ≥ 25% (odds ratio [OR]: 2.37, P = 0.008) and mean lung dose (MLD) ≥ 10 Gy (OR: 1.93, P < 0.0047). Of the 52 patients who received corticosteroids for pneumonitis after durvalumab initiation, 21 were rechallenged with durvalumab. Overall, 81% of patients met the PACIFIC study's rechallenge criteria and did not experience a severe pneumonitis relapse.High V20 and MLD were independent risk factors of symptomatic pneumonitis. More than 80% of the patients who were rechallenged with durvalumab after pneumonitis met the PACIFIC study's rechallenge criteria. Consequently, severe relapse did not occur. Cooperation between radiation and medical oncologists is important for safe chemoradiotherapy and the safe completion of durvalumab consolidation therapy." @default.
• W3198355843 created "2021-09-13" @default.
• W3198355843 creator A5005318923 @default.
• W3198355843 creator A5013472489 @default.
• W3198355843 creator A5015802846 @default.
• W3198355843 creator A5020608796 @default.
• W3198355843 creator A5024164352 @default.
• W3198355843 creator A5025251965 @default.
• W3198355843 creator A5030356607 @default.
• W3198355843 creator A5031760400 @default.
• W3198355843 creator A5034563949 @default.
• W3198355843 creator A5035163164 @default.
• W3198355843 creator A5046779019 @default.
• W3198355843 creator A5047323268 @default.
• W3198355843 creator A5047621468 @default.
• W3198355843 creator A5057947442 @default.
• W3198355843 creator A5062708568 @default.
• W3198355843 creator A5064288688 @default.
• W3198355843 creator A5071638031 @default.
• W3198355843 creator A5072875054 @default.
• W3198355843 creator A5081905843 @default.
• W3198355843 date "2021-11-01" @default.
• W3198355843 modified "2023-10-03" @default.
• W3198355843 title "Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)" @default.
• W3198355843 cites W2041803801 @default.
• W3198355843 cites W2119298887 @default.
• W3198355843 cites W2129434550 @default.
• W3198355843 cites W2161523978 @default.
• W3198355843 cites W2528393079 @default.
• W3198355843 cites W2753065806 @default.
• W3198355843 cites W2760893760 @default.
• W3198355843 cites W2893824814 @default.
• W3198355843 cites W2948397884 @default.
• W3198355843 cites W2951071083 @default.
• W3198355843 cites W2952508886 @default.
• W3198355843 cites W3015929829 @default.
• W3198355843 cites W3016806376 @default.
• W3198355843 cites W3028746215 @default.
• W3198355843 cites W3035591035 @default.
• W3198355843 cites W3046914523 @default.
• W3198355843 cites W3080826927 @default.
• W3198355843 cites W3085379405 @default.
• W3198355843 cites W3107733830 @default.
• W3198355843 cites W3114253099 @default.
• W3198355843 doi "https://doi.org/10.1016/j.lungcan.2021.08.019" @default.
• W3198355843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34543942" @default.
• W3198355843 hasPublicationYear "2021" @default.
• W3198355843 type Work @default.
• W3198355843 sameAs 3198355843 @default.
• W3198355843 citedByCount "22" @default.
• W3198355843 countsByYear W31983558432022 @default.
• W3198355843 countsByYear W31983558432023 @default.
• W3198355843 crossrefType "journal-article" @default.
• W3198355843 hasAuthorship W3198355843A5005318923 @default.
• W3198355843 hasAuthorship W3198355843A5013472489 @default.
• W3198355843 hasAuthorship W3198355843A5015802846 @default.
• W3198355843 hasAuthorship W3198355843A5020608796 @default.
• W3198355843 hasAuthorship W3198355843A5024164352 @default.
• W3198355843 hasAuthorship W3198355843A5025251965 @default.
• W3198355843 hasAuthorship W3198355843A5030356607 @default.
• W3198355843 hasAuthorship W3198355843A5031760400 @default.
• W3198355843 hasAuthorship W3198355843A5034563949 @default.
• W3198355843 hasAuthorship W3198355843A5035163164 @default.
• W3198355843 hasAuthorship W3198355843A5046779019 @default.
• W3198355843 hasAuthorship W3198355843A5047323268 @default.
• W3198355843 hasAuthorship W3198355843A5047621468 @default.
• W3198355843 hasAuthorship W3198355843A5057947442 @default.
• W3198355843 hasAuthorship W3198355843A5062708568 @default.
• W3198355843 hasAuthorship W3198355843A5064288688 @default.
• W3198355843 hasAuthorship W3198355843A5071638031 @default.
• W3198355843 hasAuthorship W3198355843A5072875054 @default.
• W3198355843 hasAuthorship W3198355843A5081905843 @default.
• W3198355843 hasConcept C121608353 @default.
• W3198355843 hasConcept C126322002 @default.
• W3198355843 hasConcept C2776256026 @default.
• W3198355843 hasConcept C2777701055 @default.
• W3198355843 hasConcept C2777714996 @default.
• W3198355843 hasConcept C2777742743 @default.
• W3198355843 hasConcept C2778424827 @default.
• W3198355843 hasConcept C2779524853 @default.
• W3198355843 hasConcept C2780030458 @default.
• W3198355843 hasConcept C509974204 @default.
• W3198355843 hasConcept C71924100 @default.
• W3198355843 hasConceptScore W3198355843C121608353 @default.
• W3198355843 hasConceptScore W3198355843C126322002 @default.
• W3198355843 hasConceptScore W3198355843C2776256026 @default.
• W3198355843 hasConceptScore W3198355843C2777701055 @default.
• W3198355843 hasConceptScore W3198355843C2777714996 @default.
• W3198355843 hasConceptScore W3198355843C2777742743 @default.
• W3198355843 hasConceptScore W3198355843C2778424827 @default.
• W3198355843 hasConceptScore W3198355843C2779524853 @default.
• W3198355843 hasConceptScore W3198355843C2780030458 @default.
• W3198355843 hasConceptScore W3198355843C509974204 @default.
• W3198355843 hasConceptScore W3198355843C71924100 @default.
• W3198355843 hasLocation W31983558431 @default.
• W3198355843 hasLocation W31983558432 @default.
• W3198355843 hasOpenAccess W3198355843 @default.
• W3198355843 hasPrimaryLocation W31983558431 @default.

• next